Olivier Delattre

CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases.

O. Delattre, A. Aurias, M. Peter, 2001, Cancer genetics and cytogenetics.

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.

Erin K. Hedlund, Michael C. Rusch, E. Mardis, 2014, Cancer discovery.

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification

O. Delattre, J. Klijanienko, H. Brisse, 2007, British Journal of Cancer.

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification

F. Speleman, J. Vandesompele, O. Delattre, 2001, International journal of cancer.

Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Société Française d'Oncologie Pédiatrique.

O. Delattre, M. Peter, J. Zucker, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction.

G. Thomas, O. Delattre, T. Melot, 1995, British Journal of Cancer.

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.

Li Ding, Xiaotu Ma, Jinghui Zhang, 2014, Cancer discovery.

Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe

W. Winkelmann, N. Willich, C. Rübe, 2015, Klinische Pädiatrie.

Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?

F. Speleman, J. Vandesompele, O. Delattre, 2001, Medical and pediatric oncology.